HTFL · Heartflow, Inc.

Track HTFL — free

$49.32 +0.41 (+0.84%) At close · Oct 2

Russell 2000 member Rebalance outlook locked

Market Cap

$4.28B

86.95M

Volume · Oct 2 1.64M Avg daily vol (3M) 1.75M

Up next

Next earnings call

Nov 12, 2026 Est · unconfirmed · in 5 wks

Latest filing: 10-Q

filed Aug 13, 2026

Q2 2026 earnings call transcript

call held Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$212.07M

Trailing 12 months

Net income (TTM)

−$118.37M

Trailing 12 months

Revenue growth YoY

+47.6%

Year over year

Operating margin

-37.8%

Trailing 12 months

P / E (TTM)

16.2

Trailing earnings · reciprocal yield 6.2%

FCF yield

-1.4%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$162.55M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+1,267.9%

Year over year · more shares

Price change (1Y)

+36.3%

Trailing year

Short interest

6.5%

Latest settlement · 3.1 days to cover

View all 115 metrics

AI Brief

Q2 FY26 earnings call · Aug 13, 2026

Q2 FY26

TL;DR. HeartFlow reported Q2 revenue of $64.1M, up 48% YoY, and raised full-year 2026 revenue guidance to $246M–$250M (from $228M–$232M) and non-GAAP gross margin guidance to ~82%, while ongoing patent and DOJ litigation and a $7.5M asset impairment were noted.

Bullish

+ Q2 revenue grew 48% YoY to $64.1M, with U.S. revenue up 51%, the fastest growth in eight quarters.
+ Raised full-year 2026 revenue guidance to $246M–$250M (40%–42% growth), up from $228M–$232M.
+ Non-GAAP net loss narrowed ~two-thirds YoY to $5.8M ($0.07/share) vs. $17.6M ($2.79/share); Adjusted EBITDA improved to ($6.7)M vs. ($10.1)M.
+ PLAC revenue of $7.8M beat expectations; full-year PLAC guidance raised to $29M–$31M and PLAC-activated accounts to ~1,250.

Bearish

− GAAP net loss widened to $15.7M ($0.18/share) from $9.2M ($1.46/share) YoY.
− R&D spend rose to $23.5M non-GAAP as the company invests ahead of revenue in pipeline and trials; total operating expenses were 111% of revenue on a GAAP basis.
− FFRCT revenue-per-case pressure remains; full-year FFRCT ASP step-ups not expected in 2026, with moderation in YoY ASP shifts only beginning in 2027.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 15.3 · calm Equity put/call 0.58

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +55%

above

Price vs 50-day avg +17%

above

RSI (14) 58

neutral

MACD trend Negative

52-week position 95%

near high

Momentum

relative strength

Very Strong

1-month return −1%

trailing

6-month return +80%

trailing

YTD return +69%

this year

Relative strength +68%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $42 › 200d $32 — 50d above 200d

Institutional flow Distributing

1 of 194 funds reported for Sep 30 · net -358 sh shares

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

6.47% of float · ▼ -7.3% MoM · 3.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

194 holders — near 1-yr high, broad support

Squeeze score 63

elevated · 0–100

Fundamentals

Strong

Revenue growth +40%

Y/Y

Gross margin 77%

expanding

EPS growth +82%

Y/Y

Free cash flow $-59.0M

Quant / Vol

risk profile

Very High

Volatility 78%

annualized · 1-yr

Max drawdown −49%

past year

ATR 4.7%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the Earnings Call filed Aug 13, 2026

full year 2026

Non-GAAP gross margin Non-GAAP Initiated 82%

Total revenue Initiated $246M – $250M

prior FY $176.03M midpoint +40.9% Y/Y

FLAG-specific revenue Initiated $29M – $31M

midterm

Non-GAAP gross margin Non-GAAP 85%

2026

Gross margin 82%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

1 · 2 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+55% Bullish

Price vs 50-day avg

+17% Bullish

RSI (14)

58 Neutral

MACD trend

Negative Bearish

52-week position

95% Bullish

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $42 › 200d $32 — 50d above 200d

Institutional flow Distributing

1 of 194 funds reported for Sep 30 · net -358 sh shares

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

6.47% of float · ▼ -7.3% MoM · 3.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

194 holders — near 1-yr high, broad support

Price context

position in its 52-week range

Range low $20 Now $49 · 95% Range high $51

vs 200-day avg +55% vs 50-day avg +17%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Adjusted EBITDA non-GAAP	-$20.33M	Six Months Ended June 30, 2026	—
Gross margin non-GAAP	82%	Six Months Ended June 30, 2026	—
Institutions globally	1,800	as of Q2 2026	—
Loss from operations non-GAAP	-$22.98M	Six Months Ended June 30, 2026	—
Net loss non-GAAP	-$18.69M	Six Months Ended June 30, 2026	—
Net loss per share, basic and diluted non-GAAP	-$0.22	Six Months Ended June 30, 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Health Information Services — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
HTFL Heartflow, Inc. this stock	$4.28B	+69.2%	+39.9%	—	6.5%
VEEV Veeva Systems Inc	$45.44B	+22.4%	+28.1%	45.9	3.1%
TEM Tempus AI, Inc.	$15.34B	+29.8%	+83.4%	—	15.6%
PMDIY Pro Medicus Ltd./ADR	$12.20B	-29.7%	—	—	0.0%
BTSG BrightSpring Health Services, Inc.	$11.02B	+60.9%	+28.2%	33.8	5.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

194

% held: 86.3%
Reported: 1 of 194
Top holder: Bain Capital Life Science…

Held Float

View

Held by Funds

Fund positions

225

View

Short & Settlement

Short Interest Falling

Shares short

5.6M

Days to cover: 3.1d
Change: -441.3K sh

View

Short Volume

Short vol %

36%

As of: Oct 2, 2026

Short Total

View

Fails to Deliver

FTD shares

331

Value: $16.2K
As of: Sep 8, 2026

View

Off-Exchange

Off-exchange %

40.9%

Week of: Aug 31, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$176.0M

Net income (FY): $-116.8M
EPS diluted: $-3.17

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Sep 9, 2026
This year: 11

View

Proposed Sales

Value

$850.9K

Shares: 16.8K
Filed: Sep 18, 2026

View

Earnings & Events

Webcasts

Last webcast

Sep 9, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
HTFL	+0.3%	-0.8%	+79.8%	-0.9%	+69.2%
SPY	-0.2%	-0.5%	+12.2%	+0.9%	+12.9%
vs SPY	+0.5%	-0.3%	+67.6%	-1.8%	+56.3%

Key facts CIK 1464521 CUSIP 42238D107 13F (30d) 4 filings 4 filers Visit website Investor relations

HTFL · Heartflow, Inc.

Price & Indicators

Up next

Metrics snapshot

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance